Paper Details

  1. Home
  2. Paper Details

SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.

Author: BiggsBeverly, ChenCaroline, DenholmJustin T, EisenDamon, LederKarin, MatchettElizabeth, McBrydeEmma S, ShultzThomas Ray, StreetAlan

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Pragmatic Clinical TrialA trial conducted in a real-world clinical setting. It evaluates the effectiveness of interventions in everyday healthcare environments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This research examines the cost-effectiveness of a 3-month course of weekly isoniazid and rifapentine (3HP) compared to a 9-month course of daily isoniazid (9H) for treating latent tuberculosis infection (LTBI) in Australia.
Paper Details　
Original Abstract of the Article :
Currently, treatment of latent tuberculosis infection (LTBI) in Australia consists most commonly of a 9-month course of isoniazid (9H). A 3-month course of weekly isoniazid and rifapentine (3HP) has been shown to be as effective as 9 months of daily isoniazid, and associated with less hepatotoxicity...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/imj.13601

データ提供：米国国立医学図書館（NLM）

Cost-Effectiveness of Self-Administered Short-Course Isoniazid and Rifapentine for Latent Tuberculosis Eradication

The current [treatment] for [latent tuberculosis infection (LTBI)] in [Australia] typically involves a [9-month course of isoniazid (9H)]. This study explores the [cost-effectiveness] of a [3-month course of weekly isoniazid and rifapentine (3HP)] as an alternative treatment option. The researchers conducted a [randomized controlled cost comparison] to assess the [efficacy and cost] of [3HP] compared to [9H]. The results suggest that [3HP] could be a [cost-effective] approach to [latent tuberculosis eradication] due to its [shorter duration] and [potential for reduced hepatotoxicity]. The study provides valuable information for policymakers and healthcare providers in making informed decisions about [LTBI treatment] strategies.

A More Efficient Path to Eradication

Imagine a long and winding path through the desert, leading to the eradication of [latent tuberculosis infection (LTBI)]. This study explores a shorter and potentially more efficient path, using a [3-month course of weekly isoniazid and rifapentine (3HP)]. The researchers found that [3HP] could be [cost-effective] compared to the traditional [9-month course of isoniazid (9H)], offering a more efficient approach to [LTBI eradication] without compromising effectiveness.

Optimizing TB Treatment

The study highlights the potential for [3HP] to become a valuable tool for [latent tuberculosis eradication]. This shorter and potentially more [cost-effective] treatment regimen could be particularly beneficial for patients who find the longer [9H] course challenging. By exploring new treatment options and evaluating their [cost-effectiveness], we can optimize [TB treatment] strategies and improve the health outcomes for patients.

Dr. Camel's Conclusion

Just as a camel adapts its journey through the desert to optimize its resources, we must find ways to optimize [TB treatment] strategies. This study, like a map guiding us through the desert of [latent tuberculosis infection], shows that [3HP] could be a more efficient and cost-effective approach to [TB eradication], offering a brighter future for those at risk.

Date :
  1. Date Completed 2018-07-19
  2. Date Revised 2018-07-19
Further Info :

Pubmed ID

29224209

DOI: Digital Object Identifier

10.1111/imj.13601

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.